Table 1.
Summary of clinical studies examined therapeutic use of hADSCs on arthritis for the last 10 years.
| Target Disorder | No. of Patients Treated (Age: Mean ± SD) |
ADSC Type | ADSC Delivery |
Study Outcome |
Year | Ref. No. | |
|---|---|---|---|---|---|---|---|
| 1 | Knee osteoarthritis | 25 (54.20 ± 9.30) | Autologous, derived from infrapatellar fat pad | Infrapatellar injection with PRP 1 | No major AEs 2 with significantly increase Lysholm, Tegner activity scale, and VAS 3 score | 2012 | [12] |
| 2 | Knee osteoarthritis | 18 (63.0 ± 12.49) | Autologous, derived from abdominal fat | Intra-articular injection | Improved function and pain without adverse events, reduced cartilage defects | 2014 | [13] |
| 3 | Knee cartilage defects | 40 (38.75 ± 9.56) | Autologous, derived from buttocks | After microfracture, intra-articular injection with fibrin glue | Improved KOOS 4 pain and symptom sub score | 2016 | [14] |
| 4 | Knee osteoarthritis | 18 (64.63 ± 9.37) | Autologous, derived from abdominal fat | Intra-articular injection | Safe, without SAEs 5 | 2016 | [15] |
| 5 | Refractory rheumatoid arthritis | 46 (53.96 ± 20.64) | Allogeneic (Cx611) | Intravenous injection | Well tolerated with no evidence of dose-related toxicity, but some AEs and SAEs | 2017 | [16] |
| 6 | Osteoarthritis | 18 (54.8 ± 17.73) | Autologous, isolated from lipoaspirates | Intra-articular injection, repeated | Safe and improved pain, function, and cartilage volume | 2018 | [17] |
| 7 | Knee osteoarthritis | 20 (54.65 ± 11.99) | Autologous, derived from abdominal fat | Intra-articular injection | No SAEs, clinically significant pain, and functional improvement | 2019 | [18] |
| 8 | Knee osteoarthritis | 12 (62.25 ± 6.50) | Autologous, derived from abdominal fat | Intra-articular injection | Significant improvement of the WOMAC 6 score without SAEs |
2019 | [19] |
| 9 | Knee osteoarthritis | 26 (55.03 ± 9.19) | Autologous, derived from abdominal fat | Intra-articular injection | Significant improvements in joint function, pain, quality of life, and cartilage regeneration | 2019 | [20] |
| 10 | Subtalar joint arthritis | 52 (56.9: 20.3–79.6) 6 | Allogeneic | ADSC loaded, partially demineralized cancellous bone (AlloSource) was grafted | Good clinical outcomes in spite of the high non-union rates | 2019 | [21] |
| 11 | Knee osteoarthritis | 18 (54.77 ± 17.79) | Allogeneic | Intra-articular injection | a possible compositional changes of cartilage, significant reduction in WOMAC 7 and SF-36 8 scores | 2019 | [22] |
1 Platelet-rich plasma (PRP), 2 adverse events (AEs), 3 visual analog scale (VAS), 4 knee injury and osteoarthritis outcome score (KOOS), 5 serious adverse events (SAEs). 6 In this study, age was presented as means with the range. 7 Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), 8 Medical Outcomes Short-Form-36 questionnaire (SF-36).